The patent for adalimumab, brand name Humira® has expired. New biosimilar versions of the drug are now available.
NASS CEO Dr Dale Webb targets the 8.5 year delay to diagnosis during Bone and Joint Week 2018
NASS has been asked a few times recently about a no-deal Brexit and the impact that this may have on the supply of medicines to the UK.
NASS welcomes the publication today by NICE of a set of Quality Standards for Spondyloarthritis. Now we need to ensure that they are implemented effectively across the country so that every AS patient, every time, gets early diagnosis and high quality care.
Many thanks to NASS Trustee Poppy, who has helped to raise awareness of the terrible impact living with AS can have on people's lives by sharing her family's story with Choice Magazine.
Looking for the chance to make a difference? Find our latest opportunities here.